KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Erasca, Inc.
Vanderbilt-Ingram Cancer Center
Tizona Therapeutics, Inc
GlaxoSmithKline
Bristol-Myers Squibb
Synthorx, Inc, a Sanofi company
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
BioAtla, Inc.
Pfizer
Sanofi
Blokhin's Russian Cancer Research Center